

MODIFIED PTO/SB708 A & B (06-03)

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/536,504
				Confirmation Number	6545
				Filing Date	May 25, 2005
				First Named Inventor	Julia CIANCI
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	Q88025

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ² (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁴
/E.P./		George He, et al., "Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802", Clin. Pharmacokinet., Dec. 1999, 37 (6), pp. 471-484	
/E.P./		Hansch, et al., "Hydrophobicity and Central Nervous System Agents: on the Principle of Minimal Hydrophobicity in Drug Design", J. Pharm. Sci., Vol. 76, No. 9, September 1987	
/E.P./		J. Driscoll, et al., "Lipophilic, Acid-Stable, Adenosine Deaminase-Activated Anti-HIV Prodrugs for Central Nervous System Delivery. 3. 6-Amino Prodrugs of 2'-β-Fluoro-2',3'-dideoxynosine", J. Med. Chem. 1996, 39, 1619-1625	
/E.P./		Y. Shechter, et al., N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl] ₃ -gentamicin C ₁ Is a Long-Acting Prodrug Derivative" J. Med. Chem. 2002, 45, 4264-4270	
/E.P./		H. Suzuki, et al., "Improvement of the Bitter Taste of Amino Acids through the Transpeptidation Reaction of Bacterial γ-Glutamyltranspeptidase", J. Agric. Food Chem. 2002, 50, 313-318	
/E.P./		TA Connors, et al., "Prodrugs in cancer chemotherapy", Stem Cells, Vol. 13, 501-511 (1995)	
/E.P./		W.M.A. Niessen, "Analysis of antibiotics by liquid chromatography-mass spectrometry", Journal Chromatography A, 812 (1998) 53-75	

Examiner Signature	/Eli Peselov/	Date Considered	11/30/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.